On November 21, 2024, Enveda Therapeutics, Inc. closed the transaction. The company has issued 24,647,353 series C preferred shares for gross proceeds of $130,000,000 in the transaction. The transaction was co-led by returning investors, Kinnevik AB and, FPV Ventures, LLC and included participation from returning investors, Lingotto Investment Management LLP, Lux Capital Management, LLC, PremjiInvest, True Venture Management, LLC, The Nature Conservancy, Dimension Management, L.P., new investors, Baillie Gifford & Co., Cresset Partners, LLC, individual investor, Henry R. Kravis.

The company has received $360 million in funding till date.